Synlogic_Logo_Blue.png
Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria
February 02, 2024 12:00 ET | Synlogic, Inc.
Findings support positive proof of mechanism, through successful degradation of methionine, precursor to homocysteine, using dietary disease model in preclinical models and healthy volunteer study ...
Synlogic_Logo_Blue.png
Synlogic Provides Corporate Update and Outlook for 2024
January 04, 2024 07:00 ET | Synlogic, Inc.
- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1...
Synlogic_Logo_Blue.png
Synlogic Announces Contract with the Air Force Research Lab
December 27, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023
December 07, 2023 07:00 ET | Synlogic, Inc.
- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE...
Synlogic_Logo_Blue.png
Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET | Synlogic, Inc.
- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial...
Synlogic_Logo_Blue.png
Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration
November 07, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Closing of $21.0 Million Underwritten Public Offering
October 03, 2023 16:15 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering
September 29, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic to Participate in Chardan’s Genetic Medicines Conference
September 21, 2023 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...
Synlogic_Logo_Blue.png
Synlogic Announces CEO Aoife Brennan Named to PharmaVoice 100
September 19, 2023 11:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to...